Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with...
Clinical Trial
Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance
Science 37’s Virtual Site Model for Clinical Research Impresses in First-of-its-Kind FDA InspectionRESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE...
Artelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
SOLANA BEACH, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling...
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today...
Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel Inhaled Therapies for Lung Diseases at the 2024 American Thoracic Society International Conference
Presentations to Include Long-term Safety and Efficacy Data from the ATLAS Trial Extension Study of AP01 (Inhaled Pirfenidone) for Pulmonary...
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell...
Excision BioTherapeutics Announces Data from the Phase 1/2 Trial of EBT-101 in HIV And In Vivo Efficacy Data in Herpes Virus and Hepatitis B
EBT-101 successfully met the primary endpoint of safety and secondary endpoint of biodistribution/immunogenicity in a Phase 1/2 study (EBT-101-001)EBT-104 successfully...
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined...
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Cash on hand of approximately $110...
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
AUSTIN, Texas, May 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted...
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
– Reports YCANTH® revenue of $3.2M for first quarter of 2024 – – Over 228 million lives now covered to date...
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
Supports expansion of Tevogen’s ExacTcell™ platform toward additional clinical trialsBolsters a financial path to positive cashflow and minimizes dilution WARREN, N.J.,...
Evaxion Receives Nasdaq Notification
COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio...
Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates
JERUSALEM, May 10, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the...
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City
SHELTON, CT / ACCESSWIRE / May 10, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum...
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology...
Zomedica Announces First Quarter 2024 Financial Results: Revenue up 14% to $6.3 Million; 66% Gross Margin, and $91 Million in Liquidity
Performance Sets New Record for First Quarter RevenueANN ARBOR, MI / ACCESSWIRE / May 9, 2024 / Zomedica Corp. (NYSE...
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO,...
Anumana’s ECG-AI™ Algorithms Honored with 2024 MedTech Breakthrough Award for “Best New Technology Solution-Cardiology”
Anumana’s innovative AI algorithms recognized for their transformative potential in cardiology - the first of which is now commercially availableCAMBRIDGE,...